SEC Form 4 · accession 0000919574-26-004259
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neal C Bradsher
Director · 10% Owner
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 5:33 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000876343
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OPTION TO PURCHASE COMMON SHARESF2,F1 | $1.30 | Jul 1, 2026 | A | 125,000 | A | — | Jul 1, 2036 | COMMON SHARES | 125,000 | 125,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $0.8977 | holding | — | — | — | — | Jul 1, 2035 | COMMON SHARES | 75,000 | 75,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $0.9541 | holding | — | — | — | — | Jul 1, 2034 | COMMON SHARES | 75,000 | 75,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $1.41 | holding | — | — | — | — | Jul 1, 2033 | COMMON SHARES | 50,000 | 50,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $1.57 | holding | — | — | — | — | Jul 1, 2032 | COMMON SHARES | 50,000 | 50,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $2.86 | holding | — | — | — | — | Jul 1, 2031 | COMMON SHARES | 50,000 | 50,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $0.8263 | holding | — | — | — | — | Jul 1, 2030 | COMMON SHARES | 40,000 | 40,000 | D |
| OPTION TO PURCHASE COMMON SHARESF3 | $1.03 | holding | — | — | — | — | Jun 30, 2029 | COMMON SHARES | 40,000 | 40,000 | D |
Explanation of responses
- F1These options will vest and become exercisable on the earlier of: (a) July 1, 2027 and (b) the date of Lineage Cell Therapeutics, Inc.'s (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the "Reporting Person") continuous service with the Issuer.
- F2These options were granted to the Reporting Person by the Issuer on July 1, 2026 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
- F3These options are currently exercisable.